Latest Therapeutics News

Page 15 of 48
Advance Zintek reports a robust 26.83% revenue increase in Q1 FY26, driven by strong growth across North America, Australia, and Europe, despite regulatory hurdles impacting zinc oxide sales in Australia.
Victor Sage
Victor Sage
2 Oct 2025
Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.
Ada Torres
Ada Torres
2 Oct 2025
Chimeric Therapeutics reports encouraging Phase 1B data from its ADVENT-AML trial, showing safety and multiple complete responses in high-risk AML patients treated with CORE-NK combined with standard therapies.
Ada Torres
Ada Torres
2 Oct 2025
Radiopharm Theranostics has received a positive safety recommendation to increase the dose of its radiotherapeutic 177Lu-RAD202 in the Phase 1 HEAT trial for HER2-positive advanced solid tumors, signaling promising early results.
Ada Torres
Ada Torres
1 Oct 2025
EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.
Ada Torres
Ada Torres
1 Oct 2025
Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.
Ada Torres
Ada Torres
30 Sept 2025
Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.
Ada Torres
Ada Torres
30 Sept 2025
Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.
Ada Torres
Ada Torres
30 Sept 2025
Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.
Ada Torres
Ada Torres
30 Sept 2025
Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.
Ada Torres
Ada Torres
30 Sept 2025
Syntara Limited has reported encouraging Phase 2a results for amsulostat combined with ruxolitinib in treating myelofibrosis, demonstrating sustained symptom improvement and spleen volume reduction over 52 weeks.
Ada Torres
Ada Torres
30 Sept 2025
Nyrada Inc. has announced successful Phase I trial results for its lead drug candidate Xolatryp, confirming safety and pharmacokinetics that pave the way for a Phase IIa trial targeting heart attack patients next year.
Ada Torres
Ada Torres
29 Sept 2025